Although lenalidomide/bortezomib/dexamethasone (RVd) and cyclophosphamide/bortezomib/dexamethasone (CyBorD) are clinically effective, their precise impacts on PC/B-cell maturation remain unclear. RVd responders further downregulated CD56, CD269, and CD329, and increased CD243. These shared and divergent modulations elucidate the molecular underpinnings of RVd and CyBorD efficacy and inform precision regimen selection.

23 hours ago

Journal

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • TNFRSF17 (TNF Receptor Superfamily Member 17) • RARA (Retinoic Acid Receptor Alpha) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PAX5 (Paired Box 5) • KLF4 (Kruppel-like factor 4) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD200 (CD200 Molecule) • IRF4 (Interferon regulatory factor 4) • CD52 (CD52 Molecule) • PRDM1 (PR/SET Domain 1) • NANOG (Nanog Homeobox) • NES (Nestin) • XBP1 (X-box-binding protein 1) • CD81 (CD81 Molecule) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2) • SLAMF7 (SLAM Family Member 7) • SIGLEC9 (Sialic Acid Binding Ig Like Lectin 9)

lenalidomide • bortezomib • cyclophosphamide

MUKEight: Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov)

P2, N=112, Completed, University of Leeds | Unknown status --> Completed | Trial completion date: Jan 2021 --> Jan 2025

1 day ago

Trial completion • Trial completion date

lenalidomide • bortezomib • cyclophosphamide • Ninlaro (ixazomib) • thalidomide

PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)

P3, N=500, Not yet recruiting, PrECOG, LLC.

2 days ago

New P3 trial

lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)

ALANIS: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)

P2, N=60, Not yet recruiting, GlaxoSmithKline | Trial completion date: Oct 2031 --> Feb 2032 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Aug 2027

3 days ago

Trial completion date • Trial initiation date • Trial primary completion date

bortezomib • cyclophosphamide • Blenrep (belantamab mafodotin-blmf)

EASE: A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment (clinicaltrials.gov)

P2, N=100, Recruiting, AHS Cancer Control Alberta | Trial completion date: May 2025 --> Dec 2026 | Trial primary completion date: May 2025 --> Dec 2026

4 days ago

Trial completion date • Trial primary completion date

bortezomib

LSP1 is a prognostic biomarker associated with apoptosis in acute myeloid leukemia. (PubMed, Biomarkers)

In addition, we also found that the NF-κB pathway-related anti-AML effect of bortezomib partially relied on LSP1. This study revealed that LSP1 plays a crucial role in the progression of AML, indicating its potential as a prognostic biomarker and therapeutic target.

9 days ago

Journal

ANXA5 (Annexin A5)

bortezomib

A case report of mixed-phenotype acute leukemia with atypical BCR::ABL1 e13a3 fusion gene. (PubMed, Medicine (Baltimore))

At present, there is no established consensus on the treatment of Ph + MPAL, and reports on cases with the atypical e13a3 BCR::ABL1 fusion are particularly scarce. This finding will bring new insights and references for the diagnosis and treatment of Ph + MPAL.

9 days ago

Journal

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)

ABL1 fusion

Venclexta (venetoclax) • dasatinib • bortezomib • cyclophosphamide

13d

TRIP13 alters mitochondrial function and promotes bortezomib resistance in multiple myeloma. (PubMed, Sci Rep)

These findings uncover a previously unrecognized role of TRIP13 in regulating mitochondrial integrity under proteotoxic stress, thereby contributing to BTZ resistance. Targeting TRIP13 may represent a novel therapeutic approach to improve outcomes in MM patients.

13 days ago

Journal

TRIP13 (Thyroid Hormone Receptor Interactor 13)

bortezomib

13d

CARTITUDE-2: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (clinicaltrials.gov)

P2, N=210, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting

13 days ago

Enrollment closed

lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • dexamethasone injection

14d

ECWM-2: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia (clinicaltrials.gov)

P2, N=53, Active, not recruiting, Christian Buske | Trial completion date: Sep 2029 --> Feb 2027

14 days ago

Trial completion date

CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)

Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib

14d

What to know about rare B-cell malignancies in 2025. (PubMed, Hematology Am Soc Hematol Educ Program)

Recent advancements in treatment involve using novel agents like bortezomib, daratumumab, and B-cell maturation antigen-targeted therapy, which are improving outcomes; however, the prognosis for relapsed disease remains poor. The best remission chances come from rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy combined with central nervous system-directed treatment. New research is ongoing for relapsed cases.

14 days ago

Review • Journal • IO biomarker

CD20 (Membrane Spanning 4-Domains A1)

Rituxan (rituximab) • bortezomib • doxorubicin hydrochloride • cyclophosphamide • Darzalex (daratumumab) • vincristine • prednisone

14d

Management of autoimmune hemolytic anemia. (PubMed, Hematology Am Soc Hematol Educ Program)

Rituximab is now the preferred second-line option for relapsed/refractory patients, comparing favorably with the traditional splenectomy. The latter is increasingly reserved for later lines together with classic immunosuppressants. Several novel treatments are in development for refractory wAIHA, encompassing drugs targeting B-cells (parsaclisib, ibrutinib, rilzabrutinib, zanubrutinib, obexelimab, ianalumab, povetacicept), plasma cells (bortezomib, daratumumab), spleen tyrosine kinase (fostamatinib, sovleplenib), and the neonatal Fc receptor (nipocalimab).

14 days ago

Review • Journal

SYK (Spleen tyrosine kinase)

Imbruvica (ibrutinib) • Rituxan (rituximab) • bortezomib • Brukinsa (zanubrutinib) • Darzalex (daratumumab) • parsaclisib (INCB50465) • Tavalisse (fostamatinib) • ianalumab (VAY736) • sovleplenib (HMPL-523)